Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982228 · ClinicalTrials.gov registry record · Phase 3
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
A Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 629
- Enrollment target
- 20
- Study locations
NCT00982228: Completed Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
NCT00982228 is a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 629 participants, below the 3,026-participant average among 338 other Diabetes trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00982228, a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 629 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine (IGlar) plus insulin aspart in patients with type 1 diabetes. The main period is registered internally at Novo Nordisk as NN1250-3583 while the extension period is registered as NN1250-3644.
Primary Outcome
Change from baseline in HbA1c after 52 weeks of treatment
Conditions Studied
Interventions
- DRUG insulin aspart
- DRUG insulin glargine
- DRUG insulin degludec
Study Locations (20)
California
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Fresno
- Novo Nordisk Investigational Site - Greenbrae
- Novo Nordisk Investigational Site - Huntington Beach
- Novo Nordisk Investigational Site - La Mesa
- Novo Nordisk Investigational Site - Los Gatos
- Novo Nordisk Investigational Site - Santa Barbara
- Novo Nordisk Investigational Site - Tustin
- Novo Nordisk Investigational Site - Ventura
- Novo Nordisk Investigational Site - Walnut Creek
Florida
- Novo Nordisk Investigational Site - Hollywood
- Novo Nordisk Investigational Site - Lake Mary
- Novo Nordisk Investigational Site - Miami
Alabama
- Novo Nordisk Investigational Site - Birmingham
- Novo Nordisk Investigational Site - Huntsville
Colorado
- Novo Nordisk Investigational Site - Aurora
- Novo Nordisk Investigational Site - Aurora
Georgia
- Novo Nordisk Investigational Site - Atlanta
- Novo Nordisk Investigational Site - Lawrenceville
Arizona
- Novo Nordisk Investigational Site - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2009-09-01 |
| Est. Completion | 2010-11-08 |
| Phase | Phase 3 |
What the finished NCT00982228 record still lists
NCT00982228 is an interventional study that assigns participants to a tested intervention. The registered 629 participants enrollment target is mid-sized for trials with a published cap, below the 3,026-participant average among 338 other Diabetes trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which insulin aspart is the first listed.
NCT00982228 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00982228 about?
NCT00982228 is a clinical study titled "Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes". This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine (IGlar) plus insulin aspart in patients with type 1 diabetes. The main per...
What is the current status of trial NCT00982228?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 629 participants. The study started on 2009-09-01. Estimated completion is 2010-11-08.
What conditions does trial NCT00982228 study?
This clinical trial studies the following conditions: Diabetes, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT00982228?
The interventions under investigation include: insulin aspart (DRUG), insulin glargine (DRUG), insulin degludec (DRUG).
Who is sponsoring clinical trial NCT00982228?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00982228 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00982228's enrollment target sits among peer trials
629 63rd of 338 higher than 276 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial to Assess Chelation Therapy in Critical Limb Ischemia
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
COMPLETED · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI